ArticleCancer medicine2023
Burden of cancers attributable to high fasting plasma glucose in the Middle East and North Africa region, 1990-2019.
Article in Cancer medicine, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 7 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
7 citing papers in PubMed, 1 synthesis or guideline pooled it, 7 citations in OpenAlex.
- Dietary recommendations for people with diabetes in special situations: a position statement report by Arabic Association for the Study of Diabetes and metabolism (AASD).Journal of health, population, and nutrition · 2024Guideline
- Nutrition transitions, obesity and T2DM in the Middle East and North Africa.Nature reviews. Endocrinology · 2026Review
- Observational
- Global burden of cancers attributable to high fasting plasma glucose from 1990 to 2021 and projections until 2031.Diabetology & metabolic syndrome · 2026Article
- Article
- Pancreatic cancer mortality trends attributable to high fasting blood sugar over the period 1990-2019 and projections up to 2040.Frontiers in endocrinology · 2024Article
- Burden of cancers attributable to high fasting plasma glucose in the Middle East and North Africa region, 1990-2019.Cancer medicine · 2023Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 5 institutions in 3 countries.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundThe present study reported the cancer deaths and disability-adjusted life years (DALYs) that were attributable to high fasting plasma glucose (HFPG) in the Middle East and North Africa (MENA) region by country, age, sex, cancer type and Socio-demographic Index (SDI), from 1990 to 2019.
methodsGlobal Burden of Disease (GBD) 2019 data were used to report the cancer-related deaths and DALYs that were attributable to HFPG, for all MENA countries over the period 1990-2019. The results were presented as numbers, population attributable fractions (PAFs) and rates (per 100,000) with 95% uncertainty intervals.
resultsIn 2019, there were an estimated 19.8 thousand (5.5-40.2) cancer deaths attributable to HFPG in MENA, which represents 4.7% (1.3-9.3) of all cancer-related deaths. The number of regional DALYs due to HFPG-related cancers was 462.2 thousand (127.3-959.5), which represents 3.8% (1.1-7.6) of all cancer-related DALYs in 2019. From 1990 to 2019, the age-standardized DALY rate of cancers attributable to HFPG (per 100,000) grew from 56.3 (14.6-121.1) to 107.0 (29.8-220.8), which was a 90.1% (64.4-127.8) increase. In 2019, the highest age-standardized DALY rate of cancers attributable to HFPG was in Qatar (270.4) and the lowest was in Sudan (75.3). The DALY rate of cancers attributable to HFPG increased with age, peaking for males in the 70-74 age group and for females in the 75-79 age group, and then decreased for both sexes. A broadly positive relationship was found between the national SDI and the national age-standardized DALY rate of all cancers attributable to FPG over the measurement period.
conclusionsThe burden of HFPG-related cancers has increased over the past three decades in MENA, and was higher than the global average in multiple age groups. Implementing a battery of preventive measures and therapeutic interventions is suggested to address the adverse effects of this modifiable risk factor.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.